Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : 2026 TeoTwawKi ... 2032 Darkest Interregnum -- Ignore unavailable to you. Want to Upgrade?

To: sense who wrote (174725)	7/13/2021 5:14:23 AM
From: TobagoJack	Read Replies (1) \| Respond to of 217778

Weaponisation enhanced. Who knows if the stuff even works. If works, hoarding and boosting not necessary and in truth ethically evil. If do not work, and folks think it works, and worse, acts as if works, into the flu season, boosted to add vaxx complications on top of CoVid complications, and all w/o benefit, and donating useless jabs also evil. Designing and building an airplane whilst flying in the thing is not a good idea. All eyes on Britain scmp.com Coronavirus: WHO frustrated as countries seek booster shots Rich countries should donate vaccines, not use boosters, WHO says Last week was fourth consecutive week of increasing Covid-19 cases globally

To: sense who wrote (174725)	7/13/2021 5:32:19 AM
From: TobagoJack	Read Replies (1) \| Respond to of 217778

we should also be worried about 'winging it' even as we 'wait for it' WHO does know what it is doing, as time-stamped utterances went, I suspect, at least no less so than any other entity https://www.reuters.com/business/healthcare-pharmaceuticals/who-warns-against-mixing-matching-covid-vaccines-2021-07-12/ WHO warns against mixing and matching COVID vaccine Reuters Healthcare & Pharmaceuticals · 4:42 PM HKTEXCLUSIVE European efforts to assess Russia’s Sputnik V vaccine stymied by data gaps The developers of Russia’s Sputnik V coronavirus vaccine have repeatedly failed to provide data that regulators deem to be standard requirements of the drug approval process, according to five people with knowledge of European efforts to assess the drug, providing new insight into the country’s struggle to win foreign acceptance of its product.